Association of p53 and p21 polymorphisms with prostate cancer

Cell cycle deregulation is common in human cancer. Alterations of the tumor-suppressor gene p53 and its downstream effector p21 have been indicated in the development of numerous human malignancies. Therefore, we hypothesize that the p53 codon 72 polymorphism, either on its own or in combination wit...

Full description

Saved in:
Bibliographic Details
Published in:Biomedical reports 2015-09, Vol.3 (5), p.707-714
Main Authors: SIVOŇOVÁ, MONIKA KMEŤOVÁ, VILČKOVÁ, MARTA, KLIMENT, JÁN, MAHMOOD, SILVIA, JUREČEKOVÁ, JANA, DUŠENKOVÁ, SVETLANA, WACZULÍKOVÁ, IVETA, SLEZÁK, PETER, DOBROTA, DUŠAN
Format: Article
Language:English
Subjects:
Apoptosis
Arginine
Cell cycle
cigarette smoking
Confidence intervals
Cyclin-dependent kinase inhibitor p21
Cyclin-dependent kinases
Deoxyribonucleic acid
Deregulation
DNA
Gene polymorphism
Genes
Genetic aspects
Genetic polymorphisms
GTP-binding protein
Health risk assessment
Kinases
p21
p53
p53 Protein
Pathogenesis
Physiological aspects
Polymerase chain reaction
Polymorphism
Population studies
Proline
Prostate cancer
Prostate-specific antigen
Proteins
Restriction fragment length polymorphism
Risk
Risk factors
Slovak population
Smoking
Statistical analysis
Studies
Tumor proteins
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cell cycle deregulation is common in human cancer. Alterations of the tumor-suppressor gene p53 and its downstream effector p21 have been indicated in the development of numerous human malignancies. Therefore, we hypothesize that the p53 codon 72 polymorphism, either on its own or in combination with p21 (C98A and C70T) polymorphisms, modifies the risk of prostate cancer within the Slovak population, and no previous studies have investigated these gene-gene interactions in the pathogenesis of prostate cancer in the Slovak population. Polymerase chain reaction-restriction fragment length polymorphism was used to determine the p53 and p21 genotypes in subjects comprising 300 prostate cancer patients and 446 healthy individuals. These 3 polymorphisms individually did not correlate with the prostate cancer risk. Conversely, the interaction between the p53 and p21 polymorphisms significantly decreased the risk of prostate cancer, with the odds ratio (OR) being 0.49 [95% confidence interval (CI), 0.27-0.86; P0.05). A decreased risk of prostate cancer association with the p21 C98A CA genotype (OR=0.58; 95% CI, 0.36-0.93; P
ISSN:2049-9434
2049-9442
DOI:10.3892/br.2015.496